

IMMUNE SAFETY AVATAR

Nonclinical mimicking of the immune system effects of immunomodulatory therapies

Deliverable 1.2 Dissemination Materials

DELIVERABLE REPORT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.











Abstract

This deliverable provides an overview of first communication and dissemination materials.

The domain of our project website was registered very early before the start of the project. The website can be reached via imsavar.eu. It went online in summer 2020 and is based on Search Engine Optimisation (SEO) to reach as much relevant stakeholders as possible. For social media the Consortium decided to use LinkedIn and Twitter as both tools are the most relevant to address the targeted stakeholder community.

We prepared overview slides as a template for individual conference presentations at the beginning of 2020. A one pager in lay language serves as an easy and quick overview and is meant to reach the non-scientific community and especially patients.

The production of print material will follow in 2021 as the COVID-19 pandemic and all associated measures to virtual events did not necessitate the need for print materials.

The stakeholder community is continuously growing. This was supported by two stakeholder workshops that took place in 2020 as well as several activities to attract patient involvement as well as e.g. stakeholders for biomarker development or other relevant scientific topics.



Document Information

Deliverable Report	D1.2: Dissemination Materials
Date	01.03.2021
Report prepared by	Fraunhofer IGB, Fraunhofer IZI
	BioSci Consulting
Project	imSAVAR - Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies Grant Agreement No.: 853988 (IMI2-2018-15-04)
Project Coordinator	Fraunhofer-Gesellschaft zur Foerderung der
	angewandten Forschung e.V. Prof. Dr. Dr. Ulrike Köhl
	Dr. Kristin Reiche
	Novartis Pharma AG
	Dr. Jonathan Moggs
	Hannah Morgan, PhD
Туре	Deliverable Report Public

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.











Table of Contents

Abst	ract	2
1.	imSAVAR Website	5
2.	Other material to build up an imSAVAR Stakeholder Community	8
Ackr	nowledgement	9



1. imSAVAR Website

The website includes general sections to inform about the overall concept and idea of imSAVAR, the impact, IMI JU as well as the partners and relevant contact details. Furthermore, a specific forum was established to provide room for discussions on relevant topics through the imSAVAR stakeholder community. A password protected log-in is required to join.

Upcoming relevant events are displayed on the front page as well as the link to our two podcast interviews with our Coordinators Prof. Dr. Dr. Ulrike Köhl and Dr. Jonathan Moggs (to be approved).

Search Engine Optimisation (SEO) is a key factor, therefore an extensive keyword analysis was performed.

Website Structure:

- Home
- Concept
 - o Challenge
 - o Approach & Objectives
 - o Impact
 - o Innovative Medicines Initiative
- Consortium
 - o Academic
 - o EFPIA Companies
 - o Associated Partners
 - o SMEs
- Forum
- News
 - o Events
- Publications
 - o Scientific Articles
 - o Project Publications
- Contact

Please find below some impressions of the website or directly visit imsavar.eu.






Figure 1: imSAVAR.eu Landing page with the vision and a list of the three relevant upcoming events.

mSAVAR		Home Concept ~	Consortium ~ Forum	News × Publications ×
	"If we really want to move forwar immunomodulatory therapies we research on predictive markers a models. With the imSAVAR proje the challenge of a better underst complexity of the human immune Ulnike Kohl / Coordinator LISTEN TO PODCAST.INTERVIEW WIT	e need much more and predictive ect we aim to tackle anding of the s system."	innovative hu enhance tran immunomodi to the develo patients." Jonathan Mo	AR team plans to characterise a range of man-relevant models and biomarkers to Islational safety assessment of ulatory therapeutics and ultimately lead pment of safer efficacious medicines for sigge / Coordinator SCAST-INTERVIEW WITH JONATHAN MOGGS >
Learn more a	bout the imSAVAR	R project	Forum	Publications
	hallenges, The interdis	ciplinary imSAVAR Engage	in lively discussions and	Have a look at our imSAVAR

Figure 2: imSAVAR.eu Landing page with Coordinator statements, link to podcast interviews and main sections below.



\• /							<u>» sign-up</u>	for newsletter	
im SAVAR	Ho	me	Concept ~	Consortium ~	Forum	News 🗸	Publications ~	Contact	
Home » Forum									
	Forum								
	As one of the aims of imSAVAR is to bring a degree of harmonisation and alignment to the process of immune safety assessment it is important that we engage with diverse stakeholders.								
	This forum is meant to discuss directly with stakeholders such as toxicologists, regulators, clinicians, researchers, societies, patients and industry. We would like to build up a strong imSAVAR stakeholder community.								
	In case you would like to discuss a new topic please get in touch with our partner <u>Scott Wagers</u> , responsible for Stakeholder engagement or write an email to imsavar@izi.fraunhofer.de.								
	Discuss with us:								
	Your status: Logged Out - You need to log in to participate in the discussion Here you can: Log In								
	You have to be manually signed up If you are not already signed up, plea details and write an email to: imsavar@izi.fraunhofer.de				ion to get your	login			

Figure 3: imSAVAR.eu Forum




Figure 4: imSAVAR.eu Blog and Latest News

imSAVAR Deliverable Report D1.2: Dissemination Materials 01.03.2021



							» sign-up	o for newsletter
im SAVAR		Home	Concept ~	Consortium 🗸	Forum	News 🗸	Publications ~	Contact
Home » Contact								
	Contact							
	Coordination:							
	Prof. Dr. Dr. Ulrike H	 Directo Immun Directo Univer Directo the Ha 	ology IZI or of the Institute f sity of Leipzig and		gy at the Leipzig	t		
	Jonathan Moggs	Resea • Novart	tive Director at Nc rch (NIBR) Is Pharma AG .moggs@novarti:	vartis Institutes for B s.com	ioMedical			

Figure 5: imSAVAR.eu Contacts

2. Other material to build up an imSAVAR Stakeholder Community

A general project presentation was prepared very early in the project. This serves as an agreed basis for partners to promote the project's concept. It can be extended with additional information required for an specific event or audience. It was designed to address the scientific community. The presentation slides are attached to this report.

The first dissemination campaign was planned and is currently being conducted. A one-pager serving as a project overview was developed, informing about the concept and objectives and built around graphs and quotes from the consortium. This was enhanced with information on desired patient involvement. Using lay language should especially help the non-scientific community to understand the content and scope of the imSAVAR project. The one-pager was distributed within the network of the consortium and first interested partners are currently being invited to meetings to discuss future collaborations.

During the second year of imSAVAR, as soon as a stakeholder community has been established, the first edition of the semi-annual Newsletter will be distributed. It will inform about current activities, results, publications and events. Our social media presence as well as the stakeholder workshops and activities will provide the basis to attract relevant recipients. The subscription to our newsletter is possible via our website imsavar.eu.



Acknowledgement

The authors would like to express their gratitude to the Innovative Medicines Initiative 2 Joint Undertaking (JU) for the financial support of this research under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.







